Review Note
Last Update: 02/18/2024 05:30 AM
Current Deck: Part 2::1. Subsites::Head and Neck::Salivary gland tumours
Published
Fields:
Front
H&N | Salivary gland | 3.8 | Estimated risk of LN involvement - Dutch data (Terhaarrd et al. IJROBP 2007)
Back
- ASTRO 2012 suggests adjuvant RT to LNs if risk >20-25%
- For parotid tumours - score >=4; treat level IB-III
- For all submandibular tumours (except T1 acinic or adenoid cystic) treat level I-III
- For hig grade minor salivar tumours inthe tongue, floor of mouth, pharynx or larynx

UCSF (university of california) 2007 250ps and MSK 1992 450pts
- Looked at elective nodal treatment
- Identified high risk factors as (failure risk 20-50%)
- High grade tumours (SCC, adenocarcinoma and undifferentiated carcinoma)
- T3/4 disease
- Primary size >4cm
Further information, not for memorising (no card)

Exam
Suggested Changes:
Deck Changes (Suggestion to move the Note to the following Deck):
Field Changes:
Tag Changes: